Zentalis Pharmaceuticals Inc Forecast, price target & analysts
Zentalis Pharmaceuticals Inc Target price 2025 - Analyst rating & recommendation
Zentalis Pharmaceuticals Inc Classifications & Recommendation:
Zentalis Pharmaceuticals Inc Price Target
| Target Price | $6.08 |
| Price | $2.02 |
| Potential |
200.88%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Zentalis Pharmaceuticals Inc 2026 .
The average Zentalis Pharmaceuticals Inc target price is $6.08.
This is
200.88%
register free of charge
$10.00
395.05%
register free of charge
$2.20
8.91%
register free of charge
|
|
| A rating was issued by 10 analysts: 5 Analysts recommend Zentalis Pharmaceuticals Inc to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Zentalis Pharmaceuticals Inc stock has an average upside potential 2026 of
200.88%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 40.63 |
9 Analysts have issued a sales forecast Zentalis Pharmaceuticals Inc 2024 . The average Zentalis Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Zentalis Pharmaceuticals Inc 2024 . The average Zentalis Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Margin
10 Zentalis Pharmaceuticals Inc Analysts have issued a net profit forecast 2024. The average Zentalis Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.47 | -2.46 |
| 0.22% | 44.97% | |
| P/E | negative | |
| EV/Sales | negative |
10 Analysts have issued a Zentalis Pharmaceuticals Inc forecast for earnings per share. The average Zentalis Pharmaceuticals Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Zentalis Pharmaceuticals Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Zentalis Pharmaceuticals Inc...
Current Zentalis Pharmaceuticals Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo | Locked ➜ Locked | Locked | Jan 30 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 29 2025 |
| UBS | Locked ➜ Locked | Locked | Jan 28 2025 |
| Guggenheim | Locked ➜ Locked | Locked | Nov 15 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 15 2024 |
| Oppenheimer | Locked ➜ Locked | Locked | Sep 16 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wells Fargo: Locked ➜ Locked
|
Jan 30 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 29 2025 |
|
Locked
UBS: Locked ➜ Locked
|
Jan 28 2025 |
|
Locked
Guggenheim: Locked ➜ Locked
|
Nov 15 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 15 2024 |
|
Locked
Oppenheimer: Locked ➜ Locked
|
Sep 16 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
